StockData
EoCene Ltd. logo

EoCene Ltd. (EOCN) stock

EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 31, 2026Score 5/30
$2.20−0.26 (-10.63%)

Close on Nov 18, 2026Market cap $2.20MP/E –Yield –

Earnings

EoCene's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2025
–
EPS, Q3 FY2025
$0.33
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of EoCene's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2025ended Sep 30, 2025Nov 26, 2025before the open––$0.33Release
Q2 FY2025ended Jun 30, 2025Aug 28, 2025before the open––$0.63Release
Q1 FY2025ended Mar 31, 2025May 22, 2025before the open––$0.62Release
Q1 FY2023ended Mar 31, 2023Jun 1, 2023before the open––$1.09Release
Q2 FY2022ended Jun 30, 2022Aug 4, 2022before the open–––Release
Q1 FY2022ended Mar 31, 2022May 2, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

EoCene has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When EoCene puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases EoCene filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?